WEST LAFAYETTE, IN--(Marketwire - May 16, 2011) - BASi (Bioanalytical Systems Inc.) (NASDAQ: BASI), a leader in contract drug discovery and development services and research instrumentation, has hired Michael Zhou, Ph.D. as its new Senior Director of Research and Development. Zhou joins BASi after working as the Director of Bioanalytical Chemistry/DMPK at Synta Pharmaceuticals Corporation in Lexington, Mass.
Zhou is a highly regarded expert on analytical/bioanalytical operations and regulatory compliance, including Good Laboratory Practice (GLP), cGMP, GCP regulations and ICH, GCLP, BMV guidelines. He has given numerous presentations and workshops on these topics at conferences around the world. He has authored more than 50 research articles.
Zhou will guide the method development program and will be BASi's lead for the discovery bioanalytical support group. "Michael's experience will consolidate our already strong reputation for developing the more challenging bioanalytical methods. In his R&D role, Michael will evaluate and implement new cost effective approaches to our bioanalytical process that will accelerate our growth and profitability," said President and Chief Executive Officer Anthony S. Chilton, Ph.D. "We will increase our international exposure as Michael represents us in industry conferences, meetings and workshops."
BASi is a drug discovery and development services company providing contract research services and instruments to the world's leading pharmaceutical companies and medical research organizations. The company, based in the Purdue Research Park, focuses on developing innovative services and products that increase efficiency and reduce the cost of taking new and generic drugs to market. Visit www.BASInc.com for more about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.